Soluble HLA Class I and Class II Molecule Levels in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients
暂无分享,去创建一个
G. Mancardi | G. Filaci | F. Puppo | F. Indiveri | M. Scudeletti | S. Brenci | P. Contini | P. Gazzola | L. Lanza | Sabrina Brenci | Marco Scudeletti | Francesco Indiveri
[1] J. Kesselring,et al. Frontiers in Multiple Sclerosis , 1998 .
[2] M. Krönke,et al. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes , 1996, Nature Medicine.
[3] N. Tsuchiya,et al. Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. , 1996, Arthritis and rheumatism.
[4] J. Antel,et al. Myelin basic protein and human coronavirus 229E cross‐reactive T cells in multiple sclerosis , 1996, Annals of neurology.
[5] F. Barkhof,et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.
[6] J. Frederiksen,et al. Acute optic neuritis: Myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system , 1995, Annals of neurology.
[7] G. Filaci,et al. Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. , 1995, Tissue antigens.
[8] Jingwu Z. Zhang,et al. Clonal expansion of myelin basic protein‐reactive T cells in patients with multiple sclerosis: Restricted T cell receptor V gene rearrangements and CDR3 sequence , 1995, European journal of immunology.
[9] S. Ferrone,et al. Serum HLA class I antigens: markers and modulators of an immune response? , 1995, Immunology today.
[10] M. Marrosu,et al. Genetic susceptibility to multiple sclerosis , 1994, Annals of neurology.
[11] A. Sadovnick,et al. Genetic epidemiology of multiple sclerosis: A survey , 1994, Annals of neurology.
[12] A. Sette,et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans , 1994, Journal of Neuroimmunology.
[13] S. Ferrone,et al. Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. , 1994, Human immunology.
[14] A. Nocera,et al. HLA class-I-soluble antigen serum levels in liver transplantation. A predictor marker of acute rejection. , 1994, Human immunology.
[15] D. Hafler,et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. , 1994, Journal of immunology.
[16] D. Ferguson,et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. , 1994, Journal of Clinical Investigation.
[17] Norbert,et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. , 1993, The Journal of clinical investigation.
[18] S. Ferrone,et al. Summary report from the first international workshop on soluble HLA antigens. Paris, August 1992. , 1993, Tissue antigens.
[19] N. Zavazava,et al. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. , 1993, Tissue antigens.
[20] C. Marboe,et al. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. , 1993, Journal of immunological methods.
[21] I. Catz,et al. Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue , 1993, Journal of the Neurological Sciences.
[22] R. Hughes. Pathogenesis of multiple sclerosis. , 1992, Journal of the Royal Society of Medicine.
[23] H. Tilg,et al. Soluble HLA class I serum concentrations increase with transplant-related complications after liver transplantation. , 1992, Journal of hepatology.
[24] F. Thinnes,et al. Quantitation of Soluble HLA Class II Molecules by an Enzyme‐Linked Immunosorbent Assay , 1991, Vox sanguinis.
[25] H. Link,et al. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls , 1991, Journal of Neuroimmunology.
[26] L. Kappos,et al. Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals , 1990, Neurology.
[27] L. Villar,et al. Soluble Class 1 antigens (sHLA) in CSF and serum of patients with HIV infection , 1990, Acta neurologica Scandinavica.
[28] J. Seidman,et al. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. , 1990, Science.
[29] H. Grosse-wilde,et al. Soluble HLA class I concentrations and GVHD after allogeneic marrow transplantation. , 1989, Transplantation.
[30] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[31] S. Ferrone,et al. HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA‐A AND B ANTIGENS BEARING MOLECULES , 1982, Transplantation.
[32] V. Quaranta,et al. Characterization of the specificity of DR monoclonal antibodies. , 1979, Transplantation proceedings.
[33] C. Barnstable,et al. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.
[34] S. Ferrone,et al. Production and characterization of DR xenoantisera: use for detection of serum DR antigens. , 1979, Journal of immunology.